These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 19398461)

  • 1. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
    Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
    J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefit of interventions driven by therapeutic drug monitoring.
    Rendón A; Núñez M; Jiménez-Nácher I; González de Requena D; González-Lahoz J; Soriano V
    HIV Med; 2005 Sep; 6(5):360-5. PubMed ID: 16156885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A
    HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
    Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C
    HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.
    Feldt T; Oette M; Kroidl A; Göbels K; Leidel R; Sagir A; Kuschak D; Häussinger D
    Eur J Med Res; 2005 Jan; 10(1):7-10. PubMed ID: 15737947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?
    Ribera E; López-Cortés LF; Soriano V; Casado JL; Mallolas J
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():41-67. PubMed ID: 16373004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
    Colombo S; Telenti A; Buclin T; Furrer H; Lee BL; Biollaz J; Decosterd LA;
    Ther Drug Monit; 2006 Jun; 28(3):332-8. PubMed ID: 16778716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Revised guideline "Antiretroviral Treatment"].
    Werkgroep antiretrovirale behandeling van de Nederlandse Vereniging van Aids Behandelaren
    Ned Tijdschr Geneeskd; 2005 Oct; 149(43):2399-405. PubMed ID: 16277129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of short-term success of antiretroviral therapy in HIV infection.
    Oette M; Kroidl A; Göbels K; Stabbert A; Menge M; Sagir A; Kuschak D; O'hanley T; Bode JG; Häussinger D
    J Antimicrob Chemother; 2006 Jul; 58(1):147-53. PubMed ID: 16687458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.
    Ciancio BC; Trotta MP; Lorenzini P; Forbici F; Visco-Comandini U; Gori C; Bonfigli S; Bellocchi MC; Sette P; D'Arrigo R; Tozzi V; Zaccarelli M; Boumis E; Narciso P; Perno CF; Antinori A
    Antivir Ther; 2003 Dec; 8(6):611-6. PubMed ID: 14760895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.